New biosimilar takes on keytruda in melanoma study
NCT ID NCT07581509
First seen May 19, 2026 · Last updated May 22, 2026 · Updated 2 times
Summary
This study tests whether a new drug called Bmab1800 works as well as the approved drug Keytruda for people with melanoma (a serious skin cancer) that has been removed by surgery. About 138 adults with stage IIB, IIC, or III melanoma will receive either Bmab1800 or Keytruda as an extra treatment to help prevent the cancer from coming back. The main goal is to compare how the body processes each drug and to check for side effects and immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH STAGE IIB, IIC, AND STAGE III MELANOMA FOLLOWING COMPLETE RESECTION (ADJUVANT SETTINGS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.